J. Tabernero

R. Salazar, J. Tabernero, R. Dienstmann, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Multi-target angiokinase inhibitors to fight resistance

Oriol Casanovas, Josep Tabernero, R. Salazar, 2014, Cell cycle.

Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet.

J. Baselga, J. Tabernero, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN

C. Cordon-Cardo, J. Baselga, J. Tabernero, 2015, Methods.

Tumor and Stem Cell Biology Constitutive HER 2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence

R. Gomis, J. Tabernero, J. Arribas, 2012 .

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

M. Stratton, H. Clevers, J. Tabernero, 2022, Nature Cancer.

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Machiels, J. Tabernero, R. Kurzrock, 2014, Clinical Cancer Research.

Oncogenesis and Colon Exhibit Distinct Patterns of Genome Instability and Gastrointestinal Adenocarcinomas of the Esophagus, Stomach,

M. Meyerson, T. Godfrey, R. Beroukhim, 2012 .

TGF-beta signalling-related markers in cancer patients with bone metastasis.

J. Baselga, J. Tabernero, J. Seoane, 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Optimal use of EGFR inhibitors: challenges, new drugs and future directions

J. Tabernero, R. Dienstmann, S. Dosso, 2012 .

Drugs in clinical trials

J. Tabernero, R. Dienstmann, I. Braña, 2011 .

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

J. Tabernero, J. Pérez-García, E. Vilar, 2007, Endocrine-related cancer.

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

M. Ratain, J. Tabernero, C. Kahatt, 2014, Clinical Cancer Research.

p95HER2–T cell bispecific antibody for breast cancer treatment

C. Klein, J. Baselga, J. Tabernero, 2018, Science Translational Medicine.

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

Pablo Tamayo, Ian F. Dunn, Shuji Ogino, 2008, Nature.

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

T. Ørntoft, C. Andersen, M. Esteller, 2014, Nature Communications.

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

R. Schlegel, J. Tabernero, P. Nuciforo, 2015, PloS one.

Cancer: A precision approach to tumour treatment

J. Tabernero, R. Dienstmann, 2017, Nature.

Back-to-back discovery, co-precision, and prevention

J. Tabernero, B. Casadei, 2020, European Heart Journal - Quality of Care and Clinical Outcomes.

Back-to-Back Discovery, Co-Precision, and Prevention

J. Tabernero, B. Casadei, 2019, JACC CardioOncology.

Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.

J. Tabernero, R. Dienstmann, 2010, Current opinion in investigational drugs.

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.

R. Salazar, J. Tabernero, R. Dienstmann, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Genomic testing in colorectal cancer: how much is enough?

R. Salazar, J. Tabernero, R. Dienstmann, 2015, Oncology.

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

J. Tabernero, E. Zamora, J. Arribas, 2022, Cancers.

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

J. Tabernero, P. Nuciforo, R. Dienstmann, 2022, Nature Medicine.

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

J. Baselga, R. Herbst, J. Tabernero, 2010 .

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

J. Tabernero, R. Dienstmann, C. Dittrich, 2015, Cancer Chemotherapy and Pharmacology.

A path to translation: How 3D patient tumor avatars enable next generation precision oncology.

Kristen M. Naegle, Benjamin J. Raphael, Clifford A. Meyer, 2022, Cancer cell.

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

J. Blay, R. Schilsky, S. Ikeda, 2022, Therapeutic advances in medical oncology.

BRAF as a target for cancer therapy.

J. Tabernero, R. Dienstmann, 2011, Anti-cancer agents in medicinal chemistry.

Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC

R. Salazar, J. Tabernero, 2016, Nature Reviews Clinical Oncology.

Efficacy and Toxicity of the Angiogenesis Inhibitor SU 5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma , Melanoma , and Soft Tissue Sarcoma 1

F. Cavalli, A. Harris, J. Baselga, 2003 .

The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.

R. Salazar, J. Tabernero, R. Dienstmann, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Circulating tumor DNA as a novel prognostic indicator

J. Tabernero, A. Vivancos, 2022, Nature Medicine.

Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors

J. Tabernero, C. Takimoto, J. Soria, 2014 .

CDK 8 is a colorectal cancer oncogene that regulates b-catenin activity

P. Tamayo, W. Hahn, M. Meyerson, 2008 .

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

R. Salazar, J. Tabernero, R. Dienstmann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

C. Perou, J. Parker, L. Carey, 2014, Journal of the National Cancer Institute.

Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis

Matthew L. Freedman, Stephen J. Chanock, Meir J. Stampfer, 2010, PLoS genetics.

Precision oncology in metastatic colorectal cancer — from biology to medicine

R. Bernards, A. Bardelli, J. Tabernero, 2021, Nature Reviews Clinical Oncology.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

J. Tabernero, P. Nuciforo, R. Dienstmann, 2018, The Journal of clinical investigation.

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

J. Tabernero, P. LoRusso, I. Braña, 2015, Targeted Oncology.

Enhancing anti-tumour efficacy with immunotherapy combinations

J. Larkin, J. Tabernero, F. Meric-Bernstam, 2020, The Lancet.

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.

C. Rubio-Perez, J. Carles, E. Felip, 2021, Radiology.

Predictive Biomarkers and Personalized Medicine A Personalized Pre-clinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

J. Tabernero, A. Prat, S. Tenbaum, 2013 .

1 β-catenin Confers Resistance to PI 3 K and AKT inhibitors and Subverts FOXO 3 a to Promote Metastasis in Colon Cancer

J. Baselga, J. Tabernero, S. Schwartz, 2012 .

Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid

N. López-Bigas, C. Rubio-Perez, J. Carles, 2018, Clinical Cancer Research.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

C. Cordon-Cardo, J. Baselga, K. Marks, 2017, Nature.

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

Francesca Molinari, Takehiko Sasazuki, Josep Tabernero, 2010, The Journal of clinical investigation.

Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer

J. Tabernero, S. Schwartz, J. Arribas, 2018, Clinical Cancer Research.

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Jorge S. Reis-Filho, Josep Tabernero, J. Reis-Filho, 2013, Nature Reviews Clinical Oncology.

Dual Mtorc1/2 and Her2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-her2 Therapy Statement of Translational Relevance

J. Baselga, J. Tabernero, C. Rommel, 2022 .

Cancer Therapy : Preclinical Dual mTORC 1 / 2 and HER 2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER 2 Therapy

J. Baselga, J. Tabernero, C. Rommel, 2012 .

The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer

Christopher A. Haiman, Li Jia, Matthew L. Freedman, 2009, Nature Genetics.

Enhancing global access to cancer medicines

J. Tabernero, F. Cardoso, G. Curigliano, 2020, CA: a cancer journal for clinicians.

A slow-cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

J. Tabernero, V. Sukumaran, V. del Marmol, 2018, Nature.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Salvatore Piscuoglio, Xavier de la Cruz, Jordi Rodon, 2015, Nature Communications.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

J. Guinney, J. Tabernero, S. Kopetz, 2017, Nature Reviews Cancer.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

C. Moskaluk, H. Frierson, G. Hampton, 2016, Oncogene.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

J. Baselga, J. Tabernero, P. Nuciforo, 2015, Clinical Cancer Research.

Micromanaging the Classification of Colon Cancer: The Role of the microRNAome

S. Gruber, J. Tabernero, E. Vilar, 2011, Clinical Cancer Research.

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion

Kristian Cibulskis, Gad Getz, Shuji Ogino, 2011, Nature Genetics.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

K. Cibulskis, S. Gabriel, E. Lander, 2014, Molecular Cancer.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

K. Cibulskis, S. Gabriel, E. Lander, 2014, Molecular Cancer.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

S. Fröhling, J. Lindberg, J. Bergh, 2020, Nature Medicine.

Development of molecular biomarkers in individualized treatment of colorectal cancer.

J. Tabernero, R. Dienstmann, L. De Mattos-Arruda, 2011, Clinical colorectal cancer.

Brush border Myosin Ia has tumor suppressor activity in the intestine

M. Kloor, L. Aaltonen, D. Arango, 2012, Proceedings of the National Academy of Sciences.

Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes

R. Salazar, J. Tabernero, R. Dienstmann, 2014, Current Colorectal Cancer Reports.

Molecular Predictors of Response to Chemotherapy in Colorectal Cancer

J. Tabernero, R. Dienstmann, E. Vilar, 2011, Cancer journal.

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

G. Parra, C. Rubio-Perez, H. Heyn, 2021, Nature Communications.

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

C. Fuchs, J. Tabernero, D. Ryan, 2013, Clinical Cancer Research.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

J. Desai, J. Tabernero, M. Brown, 2016, Targeted Oncology.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

M. Salto‐Tellez, P. Johnston, A. Bardelli, 2017, Nature Reviews Clinical Oncology.

Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer

R. Sanz-Pamplona, V. Moreno, G. Capellá, 2014 .

Improving access to oncology publications for advocates and people with cancer

J. Tabernero, R. Ferdinand, Jennifer Ghith, 2022, Cancer.

PELO negatively regulates HER receptor signalling and metastasis

J. Tabernero, J. Arribas, F. Canals, 2014, Oncogene.

TGF-β signalling-related markers in cancer patients with bone metastasis

J. Baselga, J. Tabernero, J. Seoane, 2008 .

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Rodrigo Dienstmann, Jordi Rodon, Josep Tabernero, 2015, Clinical Cancer Research.

Erratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (Nature reviews. Cancer (2017) 17 2 (79-92))

J. Guinney, J. Tabernero, L. Vermeulen, 2017 .

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

A. Jimeno, M. Hidalgo, J. Baselga, 2015, Clinical Cancer Research.

Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test

Rodrigo Dienstmann, Jordi Rodon, Josep Tabernero, 2015, Molecular oncology.

A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

J. Tabernero, A. Prat, S. Tenbaum, 2013, Clinical Cancer Research.

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

R. Salazar, J. Tabernero, P. Nuciforo, 2022, International journal of molecular sciences.

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer

D. Lambrechts, J. Tabernero, R. Dienstmann, 2021, Clinical Cancer Research.

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment

J. Tabernero, R. Dienstmann, 2016, Cancer journal.

New Approaches but the Same Flaws in the Search for Prognostic Signatures

R. Salazar, J. Tabernero, 2014, Clinical Cancer Research.

Molecular prescreening to select patient population in early clinical trials

J. Baselga, J. Tabernero, R. Dienstmann, 2012, Nature Reviews Clinical Oncology.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

J Jack Lee, Eitan Rubin, Razelle Kurzrock, 2019, Nature Medicine.

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.

J. Tabernero, J. Rodón, 2017, Cancer discovery.

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Rodrigo Dienstmann, Jordi Rodon, Irene Braña, 2011, The oncologist.

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

C. Rubio-Perez, J. Sahuquillo, J. Tabernero, 2019, Nature Communications.

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient.

J. Tabernero, C. Richards, M. Vazquez, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic medicine frontier in human solid tumors: prospects and challenges.

J. Barretina, J. Tabernero, R. Dienstmann, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical Oncology Management of Hereditary Colorectal Cancer

R. Salazar, J. Tabernero, E. Vilar, 2018 .

SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer

J. Tabernero, A. Muñoz, S. Tenbaum, 2014, Oncogene.

Molecular Medicine in Practice Molecular Pro fi ling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

J. Tabernero, R. Dienstmann, M. Alsina, 2012 .

Cardiotoxicity.

J. Tabernero, I. Braña, J. Tabernero, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

C. Rubio-Perez, J. Sahuquillo, J. Tabernero, 2019, Nature Communications.

Biomarker Discovery Strategies: DNA, RNA, and Protein

J. Tabernero, E. Vilar, 2013 .

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

Rodrigo Dienstmann, Josep Tabernero, E. Felip, 2012, Molecular oncology.

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

J. Baselga, J. Tabernero, F. Galimi, 2015, Targeted Oncology.

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

J. Tabernero, P. Nuciforo, R. Dienstmann, 2021, Clinical Cancer Research.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Weiliang Shi, J. Baselga, A. Tolcher, 2014, Clinical Cancer Research.

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

J. Tabernero, E. Vilar, J. Peréz-García, 2011, Molecular Cancer Therapeutics.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J. Tabernero, A. Italiano, J. Soria, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study.

J. Blay, J. Baselga, J. Tabernero, 2018, JCO precision oncology.

Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?

J. Baselga, J. Tabernero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The expanding role of immunotherapy.

J. Tabernero, A. Gros, C. Hierro, 2017, Cancer treatment reviews.

Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.

J. Tabernero, D. Olmos, L. De Mattos-Arruda, 2011, Future oncology.

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

T. Ørntoft, C. Andersen, M. Esteller, 2016, Nature Communications.

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

S. Fröhling, J. Lindberg, J. Bergh, 2022, Nature Cancer.

Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network

David Tamborero, Carlos Caldas, Giovanni Apolone, 2021 .

New clinical trial designs in the era of precision medicine

J. Tabernero, R. Dienstmann, I. Braña, 2019, Molecular oncology.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

M. Salto‐Tellez, P. Johnston, A. Bardelli, 2018, Nature Reviews Clinical Oncology.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

K. Cibulskis, S. Gabriel, E. Lander, 2014, Molecular Cancer.

Biomarker-driven patient selection for early clinical trials

J. Tabernero, R. Dienstmann, J. Rodón, 2013, Current opinion in oncology.

TGR Analysis in Phase I Clinical Trials—Letter

J. Tabernero, R. Dienstmann, 2014, Clinical Cancer Research.

Cancer: Pinprick diagnostics

Eduardo Vilar, Josep Tabernero, J. Tabernero, 2012, Nature.

Cancer bioMarkers database

Rodrigo Dienstmann, Jordi Rodon, Michael Philipp Schroeder, 2016 .

Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts).

S. Cedrés, J. Tabernero, P. Martínez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

F. Cavalli, A. Harris, J. Baselga, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

J. Tabernero, J. Schellens, M. Rodriguez-Ruiz, 2018 .

Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy

J. Carles, E. Felip, J. Tabernero, 2019, Annals of Oncology.

Intrinsic cancer subtypes-next steps into personalized medicine

R. Sanz-Pamplona, V. Moreno, R. Salazar, 2015, Cellular Oncology.

Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation

P. Maxwell, A. Bardelli, P. Laurent-Puig, 2016 .

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

C. Cordon-Cardo, J. Baselga, K. Marks, 2018, Nature.

Pancreatic cancer heterogeneity and response to Mek inhibition

J. Tabernero, J. Arribas, A. Vivancos, 2017, Oncogene.

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, J. Tabernero, 2015 .

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

J. Tabernero, R. Dienstmann, E. Garralda, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

S. Fröhling, J. Lindberg, J. Bergh, 2020, Nature Medicine.

Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models

J. Baselga, J. Tabernero, C. Rommel, 2011 .

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival

N. Girard, R. Schilsky, R. Berger, 2021, npj Precision Oncology.

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

J. Tabernero, R. Dienstmann, B. Markman, 2011, Recent patents on anti-cancer drug discovery.

Study of the Selective Aurora A Kinase Inhibitor 8054 in Patients with Advanced Solid Tumors : Safety , Ther rmacokinetics , and Pharmacodynamics

J. Baselga, J. Tabernero, H. Fingert, 2010 .

386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experience

J. Tabernero, R. Dienstmann, M. Alsina, 2014 .

RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer

L. Padilla, F. Mitjans, J. Tabernero, 2023, Oncogene.

ctDNA in Breast Milk for Early Detection of Pregnancy Associated Breast Cancer

J. Tabernero, P. Nuciforo, R. Dienstmann, 2021 .

A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

J. Tabernero, V. Sukumaran, V. del Marmol, 2018, Nature.

2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets

W. Hahn, G. Getz, R. Beroukhim, 2015 .

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

J. Tabernero, J. Tabernero, R. López-López, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

J. Tabernero, J. Tabernero, J. Seoane, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

A. Iafrate, E. Felip, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.

E. Felip, J. Tabernero, P. Martínez, 2012 .

Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.

J. Tabernero, R. Dienstmann, J. Rodón, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

J. Tabernero, P. Nuciforo, M. Schlumberger, 2019, Molecular Cancer Therapeutics.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

K. Cibulskis, S. Gabriel, E. Lander, 2014, Molecular Cancer.

Clinical and genomic characterization of early onset pancreatic cancer

J. Tabernero, R. Dienstmann, A. Vivancos, 2023, European Journal of Cancer.

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.

Benjamin Haibe-Kains, T. Pugh, E. Felip, 2023, Med.

Early evolutionary divergence between papillary and anaplastic thyroid cancers

J. Tabernero, P. Nuciforo, J. Tabernero, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.

E. Felip, J. Tabernero, R. Dienstmann, 2018 .

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

J. Tabernero, J. Tabernero, M. Alsina, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Development of molecular biomarkers in individualized treatment of colorectal cancer.

J. Tabernero, R. Dienstmann, L. De Mattos-Arruda, 2011, Clinical colorectal cancer.

Molecular dissection of microsatellite instable colorectal cancer.

J. Tabernero, E. Vilar, 2013, Cancer discovery.

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

R. Salazar, J. Tabernero, R. Dienstmann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer

G. Coetzee, B. Frenkel, C. Haiman, 2009, Nature Genetics.

How I treat gastric adenocarcinoma

J. Tabernero, M. Alsina, M. Diez, 2019, ESMO Open.

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

J. Tabernero, R. Dienstmann, V. Serra, 2014, Molecular Cancer Therapeutics.

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

J. Baselga, J. Tabernero, C. Rommel, 2012, Clinical Cancer Research.

Early-Stage Breast Cancer Detection in Breast Milk

J. Tabernero, P. Nuciforo, R. Dienstmann, 2023, Cancer discovery.

Longitudinal whole-exome sequencing of cell-free DNA unravels the metastatic evolutionary dynamics of BRCA2-mutated breast cancer

J. Tabernero, J. Tabernero, C. Richards, 2020, bioRxiv.

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.

F. J. Ramos, J. Tabernero, E. Martinelli, 2005, American Journal of Clinical Oncology.

Brush border Myosin Ia has tumor suppressor activity in the intestine

M. Kloor, L. Aaltonen, D. Arango, 2012, Proceedings of the National Academy of Sciences.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

M. Berger, J. Reis-Filho, J. Carles, 2015, Nature Communications.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment

J. Tabernero, R. Dienstmann, 2016, Cancer journal.

CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.

G. Coukos, T. Nayak, J. Tabernero, 2015 .